Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record.

MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trials

SANDBORN, W. J., KAMM, M. A., LICHTENSTEIN, G. R., LYNE, A., BUTLER, T., JOSEPH, R. E. · 2007 · Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background MMX™ mesalazine [LIALDA™ (US), MEZAVANT™ XL (UK and Ireland) MEZAVANT™ (elsewhere)] utilizes MMX Multi Matrix System® (MMX) technology which delivers mesalazine throughout the colon. Two phase III studies have already evaluated MMX mesalazine in patients with active, mild‐to‐moderate ulcerative colitis. Aim To provide more precise estimates of the efficacy of MMX mesalazine over placebo by combining the patient populations from the two phase III studies. Methods Combined data from two 8‐week, double‐blind, placebo‐controlled trials were analyzed. Patients randomized to MMX mesalazine 2.4 g/day (once daily or 1.2 g twice daily), 4.8 g/day (once daily) or placebo were reviewed. The primary end point was clinical and endoscopic remission (modified Ulcerative Colitis‐Disease Activity Index of ≤1 calculated as: rectal bleeding and stool frequency scores of 0, a combined Physician’s Global Assessment and sigmoidoscopy score of ≤1, no mucosal friability and a ≥1‐point reduction in sigmoidoscopy score from week 0). Results Data from 517 patients were analysed. 8‐week remission rates were 37.2% and 35.1% in the MMX mesalazine 2.4 g/day and 4.8 g/day groups, vs. 17.5% on placebo (P < 0.001, both comparisons). 8‐week complete mucosal healing rates were 32% in both MMX mesalazine groups compared with 16% on placebo. Adverse event frequency was similar in all groups. Conclusion MMX mesalazine is effective and generally well tolerated for inducing clinical and endoscopic remission of active, mild‐to‐moderate ulcerative colitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2007.03361.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 168

Metadata

Authors
SANDBORN, W. J., KAMM, M. A., LICHTENSTEIN, G. R., LYNE, A., BUTLER, T., & JOSEPH, R. E.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2007-05-04
Volume
26
Issue
2
Pages
205-215
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2065383525
Cited by
168
References
0
FWCI
8.04
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trials. https://app.cochat.ai/papers/10.1111/j.1365-2036.2007.03361.x
The paper
SANDBORN, W. J., KAMM, M. A., LICHTENSTEIN, G. R., LYNE, A., BUTLER, T., & JOSEPH, R. E. (2007). MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trials. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2007.03361.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.